FDA loses power to classify drugs as biologics based on inert proteins
H.R. 8630 — PEAT Act of 2026 · Filed by Michael Rulli (R-OH) · 12 cosponsors · Introduced Apr 30, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends federal law to prevent the FDA from classifying a drug as a 'biological product' merely because it contains a protein that has no clinical effect. The stated intent is to ensure that inactive protein components don't trigger stricter regulatory pathways designed for active biologics, potentially allowing certain drugs (particularly thyroid treatments) to follow simpler approval routes.
Why we flagged it
The bill narrows the definition of what qualifies as a 'biological product' under FDA law by excluding drugs whose only protein content is clinically inactive. This is a targeted regulatory reclassification that benefits drug manufacturers by allowing certain products to avoid stricter biologic approval and manufacturing standards.
What the text implies
- The bill does not define 'clinically inactive' — that determination will be made by manufacturers and FDA, creating potential for dispute and regulatory capture if the standard is applied loosely.
- Drugs reclassified away from biologic status may face less stringent post-market surveillance, potentially delaying detection of adverse effects that emerge in real-world use.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (especially those producing thyroid and hormone-replacement drugs); generic/biosimilar manufacturers (lower regulatory burden may accelerate market entry)